新辅助化疗后持续肌层浸润性膀胱癌的生存分析:SEER-Medicare数据
基于SEER-Medicare数据库2004-2011年pT2-4N0M0期膀胱癌根治术患者,比较新辅助化疗后持续肌层浸润与直接根治术的生存。调整混杂后,膀胱癌特异性死亡风险无差异(HR 0.72,95%CI 0.72-1.08,P=0.23),但直接根治术组全因死亡风险更高(HR 0.79,95%CI 0.67-0.94,P=0.006)。
要点
- 新辅助化疗后持续肌层浸润患者未获膀胱癌特异性生存获益
- 直接根治术组全因死亡风险更高,提示新辅助化疗有总生存获益
- pT3-T4N0M0持续病变者未见总生存获益
核心结论
- 铂类新辅助化疗后持续肌层浸润性膀胱癌患者较直接根治术获得总生存获益,但无膀胱癌特异性生存获益。
研究设计与样本
- 回顾性队列研究,利用SEER-Medicare数据库纳入2004-2011年pT2-4N0M0期接受根治性膀胱切除术的肌层浸润性膀胱癌患者。
- 采用Kaplan-Meier分析、Cox比例风险回归、Landmark分析及倾向性评分调整偏倚。
主要发现
- 调整混杂后,膀胱癌特异性死亡风险两组无差异(HR 0.72,95%CI 0.72-1.08,P=0.23)。
- 全因死亡风险直接根治术组更高(HR 0.79,95%CI 0.67-0.94,P=0.006)。
- pT3-T4N0M0持续病变患者中未见总生存获益。
临床怎么用
- 新辅助化疗后持续肌层浸润患者可考虑辅助治疗。
- 需进一步研究识别新辅助化疗应答人群。
局限性
- 可能存在选择偏倚,倾向接受新辅助化疗者预后更好。
- 回顾性数据库分析,存在未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate whether patients with persistent muscle-invasive bladder cancer (MIBC) after undergoing neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) have worse overall survival (OS) and cancer-specific survival (CSS) than patients with similar pathology who undergo RC alone. MATERIALS AND METHODS: Using the Surveillance, Epidemiology and End Results (SEER)-Medicare database, we identified the records of patients with pT2-4N0M0 disease who underwent RC, with and without NAC, for MIBC between 2004 and 2011. To evaluate survival outcomes in those with MIBC after NAC vs patients with MIBC who underwent RC alone, we used Kaplan-Meier time-to-event analysis and Cox proportional hazard regression modelling. Landmark analysis was conducted to mitigate immortal time bias. Propensity scoring was used to decrease the risk of selection bias. RESULTS: Of the 1 886 patients with persistent pT2-4 disease at the time of RC, 1505 underwent RC alone and 381 received NAC + RC. After adjusting for confounders, the propensity-weighted risk of death from bladder cancer after diagnosis did not differ between the groups (hazard ratio [HR] 0.72, 95% confidence interval [CI] 0.72-1.08; P = 0.23); however, the risk of death from all causes was worse in the RC-alone group (HR 0.79, 95% CI0.67-0.94; P = 0.006). CONCLUSIONS: Patients who had persistent MIBC after platinum-based NAC + RC vs RC alone derived an OS benefit but not a CSS benefit from NAC. This may represent a selection bias favouring patients who were selected for NAC; however, the OS benefit was not evident in patients with persistent pT3-T4N0M0 disease. This study underscores the importance of future research investigating methods to identify patients who will respond to NAC for bladder cancer. It also highlights the need to consider adjuvant therapy in patients who have persistent MIBC after NAC.
引用
- Lane G, Risk M, Fan Y, et al. Persistent muscle-invasive bladder cancer after neoadjuvant chemotherapy: an analysis of Surveillance, Epidemiology and End Results-Medicare data. BJU Int. 2018. PMID: 30126053. doi:10.1111/bju.14529
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。